Skip to main content
TipRanks
Go Ultimate75% OFF

Aligos Therapeutics (5WK0) Stock Statistics & Valuation Metrics

2 Followers

Total Valuation

Aligos Therapeutics has a market cap or net worth of EUR 10.64M. The enterprise value is EUR 39.06M.

Market Cap
EUR 10.64M
Enterprise Value
EUR 39.06M

Share Statistics

Aligos Therapeutics has 6,248,478 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding
6,248,478
Owned by Insiders
46.67%
Owned by Institutions
38.75%

Financial Efficiency

Aligos Therapeutics’s return on equity (ROE) is -0.45 and return on invested capital (ROIC) is -123.88%.

Return on Equity (ROE)
-0.45
Return on Assets (ROA)
-0.27
Return on Invested Capital (ROIC)
-123.88%
Return on Capital Employed (ROCE)
-1.31
Revenue Per Employee
26.66K
Profits Per Employee
-295.04K
Employee Count
82
Asset Turnover
0.02
Inventory Turnover
0.00

Valuation Ratios

The current PE Ratio of Aligos Therapeutics is -0.26. Aligos Therapeutics’s PEG ratio is 0.00.

PE Ratio
-0.26
PS Ratio
0.31
PB Ratio
1.54
Price to FCF
-0.15
Price to Operating Cash Flow
-0.25
PEG Ratio
0.00

Income Statement

In the last 12 months, Aligos Therapeutics had revenue of 2.19M and earned -24.19M in profits. Earnings per share was -2.45.

Revenue
2.19M
Gross Profit
1.26M
Operating Income
-87.98M
Pretax Income
-23.88M
Net Income
-24.19M
EBITDA
-22.95M
Earnings Per Share (EPS)
-2.45

Cash Flow

In the last 12 months, operating cash flow was -68.37M and capital expenditures -289,000, giving a free cash flow of -68.66M billion.

Operating Cash Flow
-68.37M
Free Cash Flow
-68.66M
Free Cash Flow per Share
-6.56

Dividends & Yields

Aligos Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share
―
Dividend Yield
―
Payout Ratio
N/A
Free Cash Flow Yield
-654.07%
Earnings Yield
-377.13%

Stock Price Statistics

Beta
1.13
52-Week Price Change
-63.61%
50-Day Moving Average
4.41
200-Day Moving Average
5.11
Relative Strength Index (RSI)
16.83
Average Volume (3m)
83

Important Dates

Aligos Therapeutics upcoming earnings date is Mar 11, 2027, TBA (Not Confirmed).

Last Earnings Date
Nov 06, 2026
Next Earnings Date
Mar 11, 2027
Ex-Dividend Date
―

Financial Position

Aligos Therapeutics as a current ratio of 3.90, with Debt / Equity ratio of 9.80%

Current Ratio
3.90
Quick Ratio
3.90
Debt to Market Cap
0.00
Net Debt to EBITDA
0.57
Interest Coverage Ratio
0.00

Taxes

In the past 12 months, Aligos Therapeutics has paid 314.00K in taxes.

Income Tax
314.00K
Effective Tax Rate
-0.01

Enterprise Valuation

Aligos Therapeutics EV to EBITDA ratio is 0.14, with an EV/FCF ratio of 0.13.

EV to Sales
-0.26
EV to EBITDA
0.14
EV to Free Cash Flow
0.13
EV to Operating Cash Flow
0.13

Balance Sheet

Aligos Therapeutics has EUR 31.09M in cash and marketable securities with EUR 11.90M in debt, giving a net cash position of EUR 19.19M billion.

Cash & Marketable Securities
EUR 31.09M
Total Debt
EUR 11.90M
Net Cash
EUR 19.19M
Net Cash Per Share
EUR 3.07
Tangible Book Value Per Share
EUR 1.08

Margins

Gross margin is 99.24%, with operating margin of -215.55%, and net profit margin of -197.01%.

Gross Margin
99.24%
Operating Margin
-215.55%
Pretax Margin
-186.65%
Net Profit Margin
-197.01%
EBITDA Margin
-182.64%
EBIT Margin
-186.65%

Analyst Forecast

The average price target for Aligos Therapeutics is EUR 45.49, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target
EUR 45.49
Price Target Upside
2350.81% Upside
Analyst Consensus
Moderate Buy
Analyst Count
1
Revenue Growth Forecast
1121.13%
EPS Growth Forecast
51.71%